Abstract:Clinical trials of investigational agents in systemic lupus erythematosus (SLE) have focused on targeting dysregulated B and T cells; however, recent translational research findings of the importance of the dysregulation of the innate immune system in SLE have led to clinical trials that target interferon. Three biologics that target type I interferons have been tested for their efficacy and safety in active SLE patients; these phase II trials have tested the hypothesis that down-regulation of interferon-regulated gene expression (the interferon signature) lessen the clinical burden of SLE. Rontalizumab, an anti-interferon-α monoclonal antibody, was studied in patients who had discontinued immunosuppressants. This study failed to show efficacy as assessed by both two outcome assessments; however, in low interferon signature patients, response was higher and corticosteroid usage was less in rontalizumab-treated patients. Sifalimumab, another anti-interferon-α monoclonal antibody, was studied in patients who remained on standard of care therapy. This study showed significantly better efficacy in patients treated with two sifalimumab dosages; significant differences were seen in the high interferon signature group. In a similar design and in a similar population as the sifalimumab study, anifrolumab, a monoclonal antibody that binds to a type I interferon receptor, was studied in patients who remained on standard of care therapy. In this study, one dosage group demonstrated efficacy and statistically significant effects were achieved in both tested dosage groups with secondary end points. Oral corticosteroid reduction to ≤7.5 mg daily was achieved in one of the tested dosage groups and organ-specific outcomes were significantly improved in that same group. For all studies, no significant differences in serious adverse effects were seen; although, herpes zoster infections were increased in sifalimumab- and anifrolumab-treated patients and influenza rates were increased in anifrolumab-treated patients. Anifrolumab is currently in pivotal phase III studies. Data appear to support the concept that targeting type I interferon in SLE patients associates with clinical efficacy and safety. Further data are forthcoming from ongoing phase III clinical trials of anifrolumab. Other drug development efforts should be considered that target plasmacytoid dendritic cells and toll like receptors given the effects these components have on interferon production.

Bench-scale investigation of chrysocolla flotation using n-octanohydroxamate collector

Type I Interferons in the Pathogenesis and Treatment of Sjögren’s Syndrome: an Update

Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned

Targeting interferons and their pathways in systemic lupus erythematosus

Immunological pathogenesis and treatment of systemic lupus erythematosus

Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?

Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies

Clinical Trials of Interferon Inhibitors in Systemic Lupus Erythematosus and Preliminary Real-World Efficacy of Anifrolumab

Interferon pathway in SLE: one key to unlocking the mystery of the disease

Paratesticular leiomyosarcoma in an elderly man.

Studies on the catecholamine resistance in fat cells from patients with phaeochromocytoma

Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Clinical considerations of the thoracic limb.

Distribution network: PV and PMSG ancillary services

Optimal Selection of IFN-α-Inducible Genes to Determine Type I Interferon Signature Improves the Diagnosis of Systemic Lupus Erythematosus

New and emerging therapies for systemic lupus erythematosus

JAK inhibitors in systemic lupus erythematosus: Translating pathogenesis into therapy

The innate immune system in human systemic lupus erythematosus.

Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New

Advances in therapeutic targets-related study on systemic lupus erythematosus